REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vancouver
Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as effective as longer infusions for patients receiving non-emergency percutaneous intervention. So said Anthony Fung at the first session of Late breaking Clinical Trials held at the American Heart Association’s annual meeting in Orlando. He talked with Peter Goodwin about his findings.
Reporting from:
American Heart Association Annual Scientific Sessions November 13-16, 2005, Dallas
In this edition:
Bryan Williams told American Heart Association attendees that
Post a comment